The genus Enterovirus (e.g. poliovirus, coxsackievirus, rhinovirus) of the Picornaviridae family of positivestrand RNA viruses includes many important pathogens linked to a range of acute and chronic diseases for which no approved antiviral therapy is available. Targeting a step in the life cycle that is highly conserved provides an attractive strategy for developing broad-range inhibitors of enterovirus infection. A step that is currently explored as a target for the development of antivirals is the formation of replication organelles, which support replication of the viral genome. To build replication organelles, enteroviruses rewire cellular machinery and hijack lipid homeostasis pathways. For example, enteroviruses exploit the PI4KIIIb-PI4P-OSBP pathway to direct cholesterol to replication organelles. Here, we uncover that TTP-8307, a known enterovirus replication inhibitor, acts through the PI4KIIIb-PI4P-OSBP pathway by directly inhibiting OSBP activity. However, despite a shared mechanism of TTP-8307 with established OSBP inhibitors (itraconazole and OSW-1), we identify a number of notable differences between these compounds. The antiviral activity of TTP-8307 extends to other viruses that require OSBP, namely the picornavirus encephalomyocarditis virus and the flavivirus hepatitis C virus.
Introduction
Enteroviruses constitute a large genus in the Picornaviridae family of positive-strand RNA [(þ)RNA] viruses, including important human pathogens (e.g. polioviruses, coxsackieviruses, echoviruses, rhinoviruses) that are associated with a range of acute and chronic diseases. Polioviruses are causative to poliomyelitis, which can lead to acute flaccid paralysis, coxsackie-and echoviruses can cause meningoencephalitis, myocarditis and pancreatitis, and rhinovirus infections are usually causing common colds, but can also lead to exacerbation of asthma and chronic obstructive pulmonary disease (reviewed in (Tapparel et al., 2013) ). Currently, polioviruses are the only enteroviruses against which a vaccine is available worldwide, while an EV-71 vaccine has recently been approved in China. Nevertheless, vaccination is not a viable strategy to combat the large number of enterovirus serotypes (>200). Hence, research efforts are aimed at developing broad-spectrum antiviral compounds, but no therapy has yet been approved for treating enteroviral infections.
Targeting a highly conserved step in the replication cycle is considered an attractive strategy to combat a broad range of enteroviruses. One such step is viral genome replication, a process that takes place on membranous structures, so-called replication organelles [recently reviewed by van der Schaar et al. (2016) ]. The viral protein 3A plays a central role in the membrane remodeling process that generates the replication organelles by recruiting host cell factors essential for replication, such as GBF1 and phosphatidylinositol 4-kinase type III beta (PI4KIIIb) (Belov et al., 2007; Hsu et al., 2010; Wessels et al., 2006) . PI4KIIIb recruitment is the first step of a pathway that enteroviruses usurp to manipulate the lipid environment of replication organelles. PI4KIIIb generates phosphatidylinositol 4-phosphate (PI4P) lipids at replication organelles, which triggers the recruitment of the cellular protein oxysterolbinding protein (OSBP) . OSBP mediates the transport of cholesterol to replication organelles in exchange for PI4P, thus driving the enrichment of cholesterol in these organelles (Arita et al., 2013 Roulin et al., 2014; Strating et al., 2015) . Compounds that target this pathway, like PI4KIIIb inhibitors (e.g. enviroxime, BF738735, GW5074, PIK93, T-00127-HEV1) and OSBP inhibitors (e.g. 25-hydroxycholesterol [25OHC], T-00127-HEV2, AN-12-H5, itraconazole [ITZ] , OSW-1), efficiently disrupt enterovirus replication (Albulescu et al., 2015a; Arita et al., 2011; Arita et al., 2013; Hsu et al., 2010; Strating et al., 2015; van der Schaar et al., 2013; van der Schaar et al., 2012) .
TTP-8307 was previously identified as a broad-spectrum inhibitor of enteroviruses, including poliovirus and coxsackievirus B3 (CVB3). Single point mutations in the non-structural protein 3A of CVB3 (e.g. V45A, I54F or H57Y) confer resistance to TTP-8307, suggesting that TTP-8307 targets 3A, but the mode of action has remained elusive . Later studies revealed that these mutations provide resistance against a number of compounds that target PI4KIIIb and OSBP (Albulescu et al., 2015a; Strating et al., 2015; van der Schaar et al., 2013; van der Schaar et al., 2012) . Collectively, these findings suggest that TTP-8307 also targets either PI4KIIIb or OSBP.
In this study, we investigated the mode of action of TTP-8307. We provide evidence that the antiviral activity of TTP-8307 is exerted through OSBP. We show that TTP-8307 inhibits the lipid transfer function of OSBP in vitro. However, we observed remarkable differences with other OSBP inhibitors. Consistently, TTP-8307 has antiviral activity against two non-related viruses that require OSBP, but not PI4KIIIb, for efficient replication, namely encephalomyocarditis virus and hepatitis C virus (Dorobantu et al., 2015; Wang et al., 2014) .
Materials and methods

Cells and reagents
HeLa R19 cells and Buffalo green monkey (BGM) cells were grown in DMEM (Lonza) with 10% FBS. HuH7 cells were cultured in EMEM (Sigma-Aldrich), 20 mM HEPES, pH 7.4, 10% FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin. Guanidine hydrochloride (Gua), dipyridamole (Sigma-Aldrich) and itraconazole (Santa Cruz) were purchased. OSW-1 was a kind gift from M. Shair (Harvard University) (Burgett et al., 2011) and BF738735 (MacLeod et al., 2013) was provided by Galapagos. Gua was dissolved in water, all other compounds in DMSO.
Plasmids
Plasmids for expression of FAPP1-PH-GFP (Balla et al., 2005) (from T. Balla, ICHD) and EGFP-OSBP , and bimolecular fluorescence complementation (BiFC) plasmids (Weber-Boyvat et al., 2015) were previously described. To generate pEGFP-CERT-SII, the ceramide transfer protein (CERT) open reading frame was amplified by PCR using a reverse primer encoding a human codon-optimized Strep-tagII and cloned into pEGFP-C1 (Clontech/Takara).
Viruses and infections
RLuc-CVB3 (wt and mutant) and RLuc-EMCV reporter viruses were generated as described before (Albulescu et al., 2015b; De Palma et al., 2009; Lanke et al., 2009; van der Schaar et al., 2012; Wessels et al., 2005) . Cells were infected in 96-well plates, treated with compounds and Renilla luciferase activity was determined as described before . For rescue experiments, cells were transfected for 24 h before infection. Hepatitis C virus antiviral assays were performed as described before (Delang et al., 2012) using HuH7 cells containing subgenomic HCV replicon I377/NS3-3'/wt (HuH 9e13) (Lohmann et al., 1999) . Replicon RNA levels were determined after 3 days using RTqPCR.
Microscopy
Microscopic analyses were performed using HeLa cells or BGM cells stably expressing FAPP1-PH-GFP grown on coverslips in 24-well plates essentially as described before . Where indicated, cells were transfected overnight with plasmids pEGFP-OSBP or pEGFP-CERT-SII using Fugene 6 (Promega). Cells were fixed with 4% paraformaldehyde, permeabilized with PBS/ 0.2% saponin/5% BSA, and immunostained with primary rabbit antibodies against OSBP and secondary Alexa488-or 594-conjugated goat-anti-rabbit antibodies (Molecular Probes). Cells were imaged using an Olympus BX60 or Nikon Eclipse Ti microscope.
For live-cell imaging experiments, HeLa cells seeded in compartmentalized CELLview petridishes (Greiner) were transfected overnight with pEGFP-OSBP. Cells were imaged on a Nikon Eclipse Ti microscope equipped with an Andor DU-897 EM-CCD camera and a humidified, CO 2 -and temperature-controlled chamber (Tokai-Hit). Cells were selected and images were acquired at 1 min intervals. During the first 30 min, cells were treated with DMSO, after which compounds were added and imaging was continued for another hour. Then, cells were washed with medium, fresh medium was added and imaging was resumed. For quantification, regions of interest were defined in the perinuclear region where a stronger OSBP signal was observed than in the rest of the cytoplasmic area (i.e. the Golgi) and the change in average fluorescence intensity in this area was quantified using ImageJ.
In vitro sterol transfer
The sterol transfer activity of OSBP was tested using the fluorescent cholesterol analogue dehydroergosterol (DHE) as previously described (Mesmin et al., 2013) . DHE is transferred by OSBP from endoplasmic reticulum (ER)-like liposomes covered with VAP-A to Golgi-like liposomes doped with dansylphosphatidylethanolamine (DNS-PE). DHE transport by OSBP resulted in F€ orster resonance energy transfer (FRET) between DHE and DNS-PE.
Liposomal float-up assay
PH-FFAT (OSBP fragment 76e408, containing the PH domain and FFAT motif, but lacking the OSBP-related domain [ORD]) was purified as described (Mesmin et al., 2013) , and the flotation experiments were done as previously detailed (Bigay and Antonny, 2005; Strating et al., 2015) . Briefly, PH-FFAT was incubated with ER-or Golgi-like liposomes with or without VAP-A and TTP-8307 as indicated. The suspension was mixed with high sucrose solution (30% w/v final sucrose concentration), and overlaid with 25% w/v sucrose solution and buffer without sucrose. After centrifugation, fractions were manually collected from the bottom with a Hamilton syringe and proteins bound to floating liposomes were analyzed by SDS-PAGE.
BiFC assay
HuH7 cells grown at 37 C to~70% confluency were transfected with BiFC plasmids (Venus N-terminal fragment [Vn]-OSBP, Vn-ORP2 or Vn-ORP4L together with Venus C-terminal fragment [Vc]-VAP-A) and a VAP-A-mCherry co-transfection marker using Lipofectamine 2000 (Invitrogen). After 24 h, cells were treated with compounds for 6 h, fixed with 4% paraformaldehyde and mounted. Imaging was performed using a Zeiss Axio Observer Z1 microscope. For quantification, whole cell signal intensities were analyzed for at least 100 cells per condition. The BiFC interaction intensities were quantified using ImageJ by measuring the total Venus BiFC signal and normalizing it to the intensity of the co-transfection marker.
Statistical analyses
Data are presented as means ± SEM. One-way ANOVA analysis was used to compare all groups versus control conditions (as indicated in the Figure legends) using a Dunnett post test. Statistical significance is indicated as * p < 0.05, **p < 0.01, ***p < 0.001.
Results
Synthesis of TTP-8307
TTP-8307 was synthesized as shown in Supplementary  Figs . 1e4. Consistent with previous observations, TTP-8307 inhibited CVB3 replication and the mutations I54F or H57Y in 3A conferred cross-resistance to TTP-8307, the PI4KIIIb inhibitor BF738735 (van der Schaar et al., 2013) and the OSBP inhibitor OSW-1 (Albulescu et al., 2015a; Burgett et al., 2011; Strating et al., 2015) (Fig. 1A) . These data imply that TTP-8307 inhibits replication by targeting the PI4KIIIb-PI4P-OSBP pathway.
TTP-8307 does not affect PI4KIIIb activity
We first examined whether TTP-8307 has any effect on PI4P production by PI4KIIIb. Since PI4KIIIb is the main enzyme producing PI4P at the Golgi, we used the Golgi PI4P sensor FAPP1-PH-GFP to specifically visualize PI4KIIIb-dependent PI4P. In vehicle-treated cells, stably expressed FAPP1-PH-GFP localized throughout the cell with a more concentrated localization in the perinuclear area, corresponding to the PI4KIIIb-containing Golgi complex (Balla et al., 2005; Strating et al., 2015; van der Schaar et al., 2012) . Like the established OSBP inhibitor ITZ and in contrast to BF738735 , treatment with TTP-8307 did not reduce but instead mildly enhanced the perinuclear FAPP1-PH-GFP signal (Fig. 1B) . This indicates that TTP-8307 does not inhibit PI4P production by PI4KIIIb and acts at another stage of the PI4KIIIb-PI4P-OSBP pathway.
TTP-8307 targets OSBP
OSBP tethers endoplasmic reticulum (ER) and trans-Golgi membranes at membrane contact sites (Fig. 1C) . Here, OSBP transfers cholesterol via its lipid transfer domain (i.e. OSBP-related domain, ORD) from the ER to the Golgi apparatus against the concentration gradient, while a PI4P counterflux along the concentration gradient provides the driving force for cholesterol transport (Mesmin et al., 2013) . At membrane contact sites, OSBP interacts via its FFAT motif with the ER proteins VAP-A and VAP-B, while docking to PI4P and Arf1 in the trans-Golgi through its PH domain. OSBP inhibitors, such as 25OHC, ITZ or OSW-1 prevent the transport of PI4P from the Golgi. Since PI4P also acts as an anchor for OSBP, compounds that inhibit the PI4P shuttling activity of OSBP (e.g. ITZ and OSW-1) prevent the removal of PI4P from the Golgi and cause an increase in Golgi PI4P levels, leading to an enhanced recruitment of OSBP (Albulescu et al., 2015a; Burgett et al., 2011; Mesmin et al., 2013; Ridgway et al., 1992; Strating et al., 2015) . Similar to ITZ and OSW-1, TTP-8307 induced an accumulation of both endogenous OSBP and exogenously expressed GFP-tagged OSBP at the Golgi, which was not observed for BF738735 (Fig. 1D and E), implying that TTP-8307 also targets OSBP.
ER-Golgi membrane contact sites host several other lipid transfer proteins whose localization and activity consequently depends on PI4P and the control of those lipids by OSBP, e.g. the ceramide transfer protein (CERT) (Fig. 1C) (Burgett et al., 2011; Peretti et al., 2008; Perry and Ridgway, 2006) . TTP-8307, like ITZ and OSW-1, induced a perinuclear accumulation of CERT, while inhibition of PI4KIIIb failed to induce a CERT accumulation (Fig. 1F) , similar to the PI4P-dependent OSBP localization ( Fig. 1D and E) .
TTP-8307 inhibits the lipid transfer activity of OSBP in vitro
To gain more insight into the mechanism how TTP-8307 inhibits OSBP, we studied whether TTP-8307 targets OSBP directly and inhibits its lipid shuttling activity using established in vitro liposomal assays (Mesmin et al., 2013) . We used a fluorescent analogue of cholesterol, i.e. dehydroergosterol (DHE), to measure the effect of TTP-8307 on OSBP-mediated sterol transport between ER-like liposomes (containing VAP-A, the ER anchor of OSBP) and Golgi-like liposomes (containing Arf1 as an OSBP anchor). The sterol-transfer activity of OSBP was inhibited by 1 mM TTP-8307, although not as strongly as by the positive control ITZ ( Fig. 2A) , showing that TTP-8307 inhibits the lipid transfer function of OSBP.
TTP-8307 may inhibit lipid transfer directly, through targeting the ORD, or indirectly, by hampering the interaction between the FFAT motif of OSBP and the ER anchor VAP-A, which is crucial for tethering ER and Golgi. Disruption of this interaction could also explain the accumulation of OSBP at the Golgi, like mutations in the FFAT motif that abrogate the interaction with VAP-A (Mesmin et al., 2013) . Liposome float-up experiments (for assay details see (Bigay and Antonny, 2005; Strating et al., 2015) and the Materials and Methods section) revealed that TTP-8307 did not disrupt the VAP-A dependent interaction of OSBP with ER-like liposomes (Fig. 2B) . Likewise, TTP-8307 did not disrupt the interaction of OSBP with PI4P-containing Golgi-like liposomes (Fig. 2B) .
Ligand binding to the ORD was suggested to negatively regulate the interaction between VAP-A and the FFAT motifs of OSBP and several of its family members (OSBP-related proteins, ORPs) (Rocha et al., 2009; Weber-Boyvat et al., 2015) . To assess whether TTP-8307 also affects the OSBP FFAT/VAP-A interaction, we used an established bimolecular fluorescence complementation (BiFC) assay (for technical details see (Kerppola, 2008; Weber-Boyvat et al., 2015) and the Materials and Methods section), which allows detection of ligand binding effects. Full-length OSBP was fused to the aminoterminal fragment of the Venus fluorescent protein and VAP-A to the carboxy-terminal fragment. Upon interaction of the FFAT motif of OSBP and VAP-A, the two Venus fragments meet and reconstitute at an MOI of 0.1, treated with compounds, and luciferase levels at 7 h post infection (p.i.) were determined. The well-known replication inhibitor guanidine HCl (Gua) was used as positive control, as the 3A mutations do not confer resistance against this inhibitor. Statistical significance between mutants and wt was assessed by one-way ANOVA analysis with Dunnett post test; **p < 0.01, ***p < 0.001. (B) BGM cells stably expressing FAPP1-PH-GFP were treated with DMSO, 10 mM TTP-8307, 10 mM ITZ or 1 mM BF738735 for 1 h, fixed and imaged by wide field fluorescence microscopy. (C) Schematic of the proteins discussed in this manuscript that localize to the ER-Golgi membrane contact site. PI4Ks (particularly PI4KIIIb) phosphorylate PI lipids to generate PI4P, which are enriched at the Golgi. OSBP docks to PI4P lipids and the small GTPase Arf1 (not shown) at the Golgi through its pleckstrin homology (PH) domain, while simultaneously binding to the ER-localized membrane protein VAP-A/B (VAP) through its FFAT motif. OSBP mediates a cholesterol/PI4P exchange to accumulate cholesterol at the Golgi (see text). Sac1 removes the phosphate from PI4P, thus keeping the PI4P gradient intact and allowing continuous cholesterol transport. The ceramide transporter, CERT, also docks to the Golgi via its PH domain depending on PI4P and Arf1 (not shown), and to the ER via a FFAT/VAP interaction. CERT mediates the transport of ceramide lipids from their production site in the ER to the Golgi, where ceramide is converted into sphingomyelin (not shown). The PI4P sensor FAPP1-PH-GFP (used in B) incorporates the PH domain of FAPP1, which localizes to Golgi through PI4P and Arf1 (not shown), to detect PI4P lipids. Pharmacologic inhibitors of the lipid shuttling activity of OSBP (e.g. ITZ, OSW-1) prevent the OSBP-mediated removal of PI4P from the Golgi, which leads to an accumulation of PI4P at the Golgi and a PI4P-dependent recruitment of proteins like OSBP, CERT and FAPP1-PH-GFP. In contrast, inhibitors of PI4KIIIb (e.g. BF738735) prevent PI4P production and PI4P-dependent a fluorescent protein. Monitoring the BiFC fluorescence allowed us to assess the strength of the OSBP FFAT/VAP-A interaction and the effect of compounds on this interaction. The ORD-targeting compound ITZ slightly, but not significantly, reduced the BiFC signal (Fig. 2C) . This is in line with previous observations for other ORPs that ligands mildly affect the FFAT/VAP-A interaction (Weber-Boyvat et al., 2015) . TTP-8307 slightly reduced the BiFC signal (Fig. 2C) , suggesting that TTP-8307 also targets the ORD of OSBP. Besides OSBP, ITZ likely also targets ORP4L , the closest homolog of OSBP. Indeed, we found that ITZ affected the ORP4L/VAP-A BiFC signal (Fig. 2C) . Likewise, TTP-8307 inhibited the interaction between ORP4L and VAP-A, but not between ORP2 and VAP-A (Fig. 2C) . Taken together, our results are in line with the idea that TTP-8307 inhibits the lipid shuttling function of OSBP by targeting the ORD.
OSBP overexpression does not rescue virus replication in the presence of TTP-8307
We previously demonstrated that OSBP overexpression restores CVB3 replication in the presence of the OSBP inhibitors ITZ and OSW-1, but not in the presence of PI4KIIIb inhibitors (Albulescu et al., 2015a; Strating et al., 2015) . Conversely, overexpression of PI4KIIIb countered the effect of several PI4KIIIb inhibitors, but not OSBP inhibitors, on CVB3 replication (Albulescu et al., 2015a; Strating et al., 2015; van der Schaar et al., 2013; van der Schaar et al., 2012) . To our surprise, although all of our data indicate that TTP-8307 targets OSBP, the antiviral effect of TTP-8307 on CVB3 replication could not be rescued by OSBP overexpression, nor did the overexpression of PI4KIIIb reverse the effect of TTP-8307 (Fig. 3A) . Also overexpression of ORP4L, which can rescue the inhibitory effect of OSW-1, failed to abolish the effect of TTP-8307 on CVB3 replication. Hence, there is a surprising difference between the OSBP inhibitors TTP-8307, ITZ and OSW-1.
Effect of TTP-8307 on OSBP localization is reversible
To investigate whether there are other differences between TTP-8307, ITZ and OSW-1, we compared the effect of the compounds on the dynamics and reversibility of OSBP redistribution using live-cell imaging ( Fig. 3B and C, and Supplementary Fig. 5 ). Within a few minutes after adding the compounds, the initial faint EGFP-OSBP fluorescence at the Golgi clearly increased in cells treated with any of the OSBP inhibitors, but not in cells treated with BF738735. Importantly, TTP-8307 induced a similarly rapid accumulation of OSBP as ITZ and OSW-1, which are known to interact with OSBP (Burgett et al., 2011; Strating et al., 2015) . Of note, compounds that interfere with cellular cholesterol homeostasis, e.g. the endosomal cholesterol shuttling inhibitor U18666A, also induce OSBP accumulation at the Golgi, but this indirect accumulation of OSBP is orders of magnitude slower (first effects were only visible 3e4 h after U18666A addition, whereas OSBP accumulation became already apparent within three minutes of TTP-8307, ITZ or OSW-1 addition) (Fig. 3C, and Supplementary Figs. 5 and 6) . Hence, the fast OSBP accumulation in response to TTP-8307 can only be explained by direct targeting of OSBP by TTP-8307 and is in line with the liposomal sterol shuttling data ( Fig. 2A) .
After one hour of drug treatment, during which the signal intensity at the Golgi continued to increase, the compounds were washed away and imaging was continued (Fig. 3B and C) . In the case of TTP-8307 and ITZ, OSBP fluorescence intensity at the Golgi rapidly decreased, while for OSW-1 it remained stable, thus again revealing a difference between the three OSBP inhibitors.
TTP-8307 inhibits other OSBP-dependent viruses
Two (þ)RNA viruses unrelated to enteroviruses were recently reported to also require OSBP for efficient replication and to be sensitive to OSBP-inhibitors, namely encephalomyocarditis virus (EMCV), belonging to the Cardiovirus genus of the Picornaviridae family, and hepatitis C virus (HCV), a Hepacivirus genus member of the Flaviviridae family (Dorobantu et al., 2015; Strating et al., 2015; Wang et al., 2014) . In line with our conclusion that TTP-8307 targets OSBP, we observed that both EMCV and HCV were inhibited by TTP-8307 ( Fig. 4A and B) . Importantly, while HCV dependence on PI4KIIIb was reported to be genotype-specific, with genotype 1b depending on both PI4KIIIa and PI4KIIIb (Berger et al., 2009; Borawski et al., 2009; Reiss et al., 2011; Trotard et al., 2009 ), EMCV does not require PI4KIIIb for replication and relies on PI4KIIIa instead (Dorobantu et al., 2015) . Taken together, we demonstrate that TTP-8307 exerts broad-spectrum antiviral activity against enteroviruses, EMCV and HCV, most likely by targeting OSBP.
Discussion
We observed many similarities between TTP-8307 and the known OSBP-inhibitors ITZ and OSW-1. Like ITZ and OSW-1, TTP-8307 did not reduce PI4P levels at the Golgi, indicating that it does not inhibit the activity of PI4KIIIb. Instead, all three compounds caused increased PI4P levels, correlating with OSBP redistribution to the Golgi. TTP-8307 induced OSBP redistribution in a similar time frame as ITZ and OSW-1, suggesting that TTP-8307 also targets OSBP directly. Furthermore, all three compounds triggered Golgi accumulation of CERT, a lipid transfer protein that acts in concert with OSBP at ER-Golgi membrane contact sites (Peretti et al., 2008; Perry and Ridgway, 2006) . The reduction in OSBP-mediated DHE transfer in vitro demonstrates that TTP-8307 disrupts the lipid shuttling function of OSBP directly. The liposomal float-up experiments and the BiFC data collectively suggest that TTP-8307, like ITZ , inhibits OSBP activity by targeting the ORD directly. In line with targeting OSBP, TTP-8307 also inhibited the OSBP-dependent viruses EMCV and HCV.
Despite all similarities between TTP-8307, ITZ and OSW-1, we also found a number of surprising differences. Although all our results support OSBP as the target responsible for the antiviral activity of TTP-8307, virus replication in presence of TTP-8307, unlike ITZ or OSW-1 (Albulescu et al., 2015a; Strating et al., 2015) , could not be rescued by overexpressing OSBP. The most straightforward explanation for this surprising observation is that TTP-8307 has additional targets that are relevant for virus replication and that prevent OSBP overexpression alone from counteracting the inhibitory action of TTP-8307. The observation that the I54F or H57Y substitutions in 3A provide less resistance to TTP-8307 than to OSW-1 or BF738735 is also compatible with the idea that TTP-8307 has additional targets that mediate the antiviral activity. Another difference between the compounds is that the accumulation of OSBP at the Golgi was readily reversed upon removal of TTP-8307 or ITZ, while OSBP remained concentrated at the Golgi upon OSW-1 removal. These dissimilarities between may well be the result of differences in binding affinity or the stability of proteininhibitor complexes, but this remains to be established.
Both ITZ and OSW-1 were shown to also have antitumor effects via a number of different targets (Antonarakis et al., 2013; Burgett et al., 2011; Kim et al., 2010 Kim et al., , 2014 Nacev et al., 2011; Rudin et al., 2013; Xu et al., 2010) . While for ITZ no direct link between OSBP inhibition and anti-cancer activity has been made so far, the anticancer effect of OSW-1 was shown to depend on both OSBP and ORP4L (Burgett et al., 2011) . Possibly, some cancer cell types are more sensitive to OSBP inhibition than to ORP4L inhibition, or vice Statistical significance of rescue compared to the negative control (GalT) was assessed by one-way ANOVA analysis with Dunnett post test; ***p < 0.001 (B and C) HeLa cells transiently expressing EGFP-OSBP were treated with DMSO for 30 min to determine baseline, then with 10 mM TTP-8307, 10 mM ITZ, 10 nM OSW-1 or 1 mM BF738735, and the relocalization of OSBP was analyzed by live-cell imaging. After 1 h of compound treatment, imaging was continued for another 1 h in the absence of compounds. Stills from the early relocalization phase, showing the fast accumulation of OSBP, are displayed in Supplementary Fig. 5 . (C) Quantification of the relative GFP-OSBP signal at the Golgi in five cells for each condition from (B). Scale bars correspond to 10 mm.
versa, but this remains to be investigated. Regardless, given our findings that TTP-8307 targets OSBP and, based on the BiFC assay, possibly ORP4L as well, TTP-8307 may also be able to inhibit cancer cell growth or exert indirect antitumor activities. Therefore, potential applications for TTP-8307 can go beyond its broad-range antiviral effect, and its potential as an anti-cancer agent should be explored.
